The global chloroform market has staged a notable differentiated upward recovery in the third quarter of 2026 after a prolonged weak consolidation in the first half of the year. As a critical basic methane chloride chemical, chloroform is widely utilized in refrigerant raw material synthesis, high-purity pharmaceutical intermediate processing, industrial solvent extraction, and fine chemical manufacturing, serving as an essential link connecting the fluorochemical and biopharmaceutical industries. Driven by phased production suspensions at major domestic production bases and the continuous recovery of downstream high-end demand, the chloroform market officially entered a clear upward channel in early September, forming a unique market pattern characterized by overall adequate social supply and phased regional spot shortages.
The domestic chloroform industry features a highly concentrated market structure with strong leading enterprise pricing power. Top domestic manufacturers including Dongying Huatai and Jiangxi Liwen collectively account for more than 70% of China’s total chloroform production capacity, enabling effective industry supply regulation and stable market guidance. In 2026, China’s annual chloroform output is expected to range from 1.05 million to 1.1 million tons, with the industry’s average operating rate steadily maintained at 70% to 75%, ensuring sufficient overall market supply to meet domestic and export demand. Despite the loose macro supply environment, concentrated equipment maintenance and technical transformation projects in Shandong and East China production zones during Q3 triggered short-term production reductions, rapidly depleting regional spot inventories and prompting proactive price hikes by mainstream manufacturers.
Real-time market monitoring data shows that China’s benchmark chloroform price stood at 2116.67 yuan per ton in early September 2026, marking a 5.8% month-on-month increase. Multiple leading enterprises have successively raised ex-factory quotations, continuously lifting the overall market transaction focus. Unlike previous passive price fluctuations driven by raw material cost changes, this round of market rebound is primarily fueled by improved demand prosperity and phased supply shortages, featuring stronger market autonomy and more sustainable upward momentum.
The recovering refrigerant industry constitutes the core driving force for the chloroform market’s turnaround. After completing inventory destocking and adjustment in the first half of 2026, the global mainstream refrigerant market ushered in a steady recovery starting in Q2. Downstream refrigerant manufacturers have gradually increased operating loads, driving month-by-month growth in raw material demand for chloroform. With the arrival of the traditional peak sales season for civil and industrial refrigeration equipment in the second half of the year, terminal market demand for various mainstream refrigerants continues to rise, providing stable and continuous rigid demand support for the chloroform industry.
Beyond the refrigerant sector, the booming high-end pharmaceutical raw material market has become a new growth driver for chloroform consumption. High-purity chloroform is an indispensable extraction solvent and synthetic intermediate in the production of biochemical reagents and high-value pharmaceutical intermediates. Benefiting from the overall recovery of the global biopharmaceutical manufacturing industry and the rapid expansion of China’s fine pharmaceutical sector, market demand for high-purity chloroform has achieved steady year-on-year growth. This high-end demand optimization has effectively improved the chloroform market’s demand structure, enhanced industry profitability, and strengthened the sector’s ability to resist market risks.
Global industrial regulation upgrades are also reshaping the long-term development pattern of the chloroform industry. The EU updated and tightened REACH environmental management standards for chloroform in 2026, significantly raising environmental compliance and production threshold requirements for global manufacturers. A large number of small and medium-sized manufacturers with backward production processes and substandard environmental protection facilities in Europe and Southeast Asia have been phased out of the market. The continuous elimination of backward capacity has reduced disorderly low-price competition in the global market, creating a standardized and high-quality development environment for large-scale compliant chloroform producers in China.
On the cost side, chloroform’s core raw materials methanol and liquid chlorine maintained stable and moderately firm prices in Q3 2026. The stable raw material price level keeps manufacturers’ comprehensive production costs within a reasonable range, with no excessive cost pressure. Coupled with rising product market prices, enterprise profit margins have been significantly repaired, effectively stimulating production enthusiasm and active shipment willingness across the industry.
Looking forward to the fourth quarter of 2026, the domestic chloroform market is expected to maintain a fluctuating upward trend. Industry institutions predict that mainstream chloroform prices in East China are likely to break through 3000 yuan per ton in the short term. Medium-term market trends will depend on three key factors: raw material price fluctuations of methanol and liquid chlorine, the sustainability of downstream refrigerant and pharmaceutical demand growth, and the capacity resumption progress of overhauled production units. Overall, the chloroform market will maintain high prosperity in the late 2026 period, with supply-demand structural optimization continuing to be the core operating theme of the industry.
Post time: Sep-14-2026